Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - A prospective cohort study.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Cytoreduction Surgical Procedures* ; Hyperthermia, Induced* ; Platelet Activation*; Peritoneal Neoplasms/*blood ; Peritoneal Neoplasms/*therapy ; Thrombin/*metabolism; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Peritoneal Neoplasms/pathology ; Prospective Studies ; Thrombelastography ; Thrombin Time

Background and Objectives: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC), indicated for patients with peritoneal metastases from digestive or gynecological malignancies alike, demonstrates a considerable impact on hemostatic metabolism, both on platelet and on coagulation level. The potential hemostatic interference in CRS and HIPEC is phase dependent. The hypothesis of this prospective cohort study is that the procedure exposed an increased thrombotic risk, resulting in a faster and increased thrombin generation and hyper platelet function.
Methods: This study explores the combined use of ROTEM (rotational thromboelastometry), PACT (platelet activation test) and CAT (thrombin generation test) assays during CRS and HIPEC with a follow-up of 7 days postoperative in 27 patients with confirmed histological diagnosis of peritoneal disease.
Results: Platelet reactivity (relative to before incision values) to CRP (collagen-related peptide) (p value 0.02) and TRAP (thrombin receptor activator peptide) (p value 0.048) seems to be slightly reduced during CRS and HIPEC with regard to αIIbβ3 activation, while P-selectin expression is not affected. During surgery, CAT demonstrates that, the LT (lagtime) (p value 0.0003) and TTP (time-to-thrombin peak) values (p value 0.002) decrease while and the TP (thrombin peak) (p value 0.004) and ETP (endogenous thrombin potential) (p value 0.02) increase. Subsequently, after surgery, the LT and TTP increase and ETP and TP decrease in time. ROTEM EXTEM (extrinsic) MCF (maximum clot firmness) (p value 0.005), INTEM (intrinsic) MCF (p value 0.003) and FIBTEM (fibrinogen) MCF (p value <0.001) decreased during CRS. At day 7 INTEM and FIBTEM MCF values (p values of 0.004 and <0.001) were significantly higher than before surgery. No considerable changes in platelet count and hemoglobin concentration and absence of leukopenia are noticed.
Conclusion: This approach detects changes in coagulation much earlier than noticed by standard coagulation tests.
Competing Interests: The authors have declared that no competing interests exist.

Drug Saf. 1995 Oct;13(4):228-44. (PMID: 8573296)
J Thromb Haemost. 2011 Aug;9(8):1562-71. (PMID: 21649851)
Hematol Oncol Clin North Am. 2013 Jun;27(3):521-40. (PMID: 23714310)
Ann Oncol. 2012 Aug;23(8):1937-42. (PMID: 22534771)
Jpn J Clin Oncol. 2011 Jan;41(1):125-9. (PMID: 20826449)
World J Surg Oncol. 2011 Dec 19;9:169. (PMID: 22182345)
Ann Surg Oncol. 2013 Apr;20(4):1082-7. (PMID: 23456387)
Cancer Res. 1979 Jun;39(6 Pt 2):2264-8. (PMID: 87263)
Scanning Microsc. 1996;10(3):805-18; discussion 819. (PMID: 9813641)
Vet Immunol Immunopathol. 1999 Aug 2;69(2-4):185-99. (PMID: 10507304)
Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi. (PMID: 11641098)
Int J Artif Organs. 2014 Sep;37(9):1-12. (PMID: 25262634)
Int J Pharm. 2015 Feb 1;479(1):23-7. (PMID: 25535649)
Br J Surg. 2014 Dec;101(13):1758-65. (PMID: 25329419)
Cir Esp. 2015 Oct;93(8):496-501. (PMID: 25882334)
J Surg Res. 2013 Jan;179(1):e133-9. (PMID: 22480844)
Curr Drug Targets. 2002 Jun;3(3):247-58. (PMID: 12041738)
Thromb Haemost. 2014 Mar 3;111(3):447-57. (PMID: 24258426)
Paediatr Anaesth. 2013 Mar;23(3):222-7. (PMID: 23302040)
J Am Coll Cardiol. 2014 Jul 29;64(4):361-8. (PMID: 25060370)
JRSM Open. 2014 May 06;5(6):2054270414531126. (PMID: 25057402)
Int J Med Sci. 2012;9(1):33-9. (PMID: 22211087)
Ann Surg. 1995 Jan;221(1):29-42. (PMID: 7826158)
Ann Intern Med. 1979 Mar;90(3):317-23. (PMID: 426399)
World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):434-9. (PMID: 27602245)
Int J Hyperthermia. 2002 Jul-Aug;18(4):307-15. (PMID: 12079586)
Eur J Appl Physiol. 2008 Mar;102(5):547-54. (PMID: 18043935)
Thromb Res. 2014 Dec;134(6):1350-7. (PMID: 25307422)
Semin Immunopathol. 2012 Jan;34(1):43-62. (PMID: 22037947)
PLoS One. 2015 Oct 30;10(10):e0141797. (PMID: 26516774)
Ann Surg Oncol. 2012 Dec;19(13):4244-51. (PMID: 22805865)
J Vet Emerg Crit Care (San Antonio). 2012 Oct;22(5):550-7. (PMID: 22931303)
Gastroenterol Res Pract. 2012;2012:378064. (PMID: 22778722)
Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53. (PMID: 13679651)
Transfus Med Hemother. 2013 Apr;40(2):117-25. (PMID: 23652405)
Int J Hyperthermia. 2015;31(8):857-62. (PMID: 26446799)
Cancer. 1989 Apr 1;63(7):1303-7. (PMID: 2920359)
AAPS J. 2016 Jan;18(1):239-50. (PMID: 26577587)
Pathophysiol Haemost Thromb. 2003;33(1):4-15. (PMID: 12853707)
Cancer Chemother Pharmacol. 2013 Mar;71(3):693-704. (PMID: 23274396)
Intern Med. 2013;52(5):611-5. (PMID: 23448774)
Thromb Res. 1986 Aug 1;43(3):353-60. (PMID: 3738868)
Blood Coagul Fibrinolysis. 2015 Sep;26(6):613-20. (PMID: 26083991)
World J Surg Oncol. 2014 May 01;12:136. (PMID: 24886171)
Thromb Res. 2013 Jan;131(1):3-11. (PMID: 23158401)
Anticancer Drugs. 1990 Oct;1(1):5-13. (PMID: 2131038)
Platelets. 1999;10(2-3):137-40. (PMID: 16801083)
J Trauma Acute Care Surg. 2014 Dec;77(6):839-45. (PMID: 25099452)
Clin Oncol. 1976 Sep;2(3):219-25. (PMID: 1009705)
Hepatogastroenterology. 2011 May-Jun;58(107-108):802-8. (PMID: 21830394)
J Surg Res. 2013 Dec;185(2):e93-100. (PMID: 23856126)
Biomed Res Int. 2014;2014:456569. (PMID: 24895576)
Anaesthesia. 2008 Apr;63(4):389-95. (PMID: 18336490)
J Cardiothorac Vasc Anesth. 2014 Apr;28(2):210-6. (PMID: 24630470)
Transfus Med Rev. 2013 Jul;27(3):137-45. (PMID: 23845922)
Langenbecks Arch Surg. 2015 Jan;400(1):37-48. (PMID: 25319432)
J Gastrointest Oncol. 2016 Feb;7(1):99-111. (PMID: 26941988)
Oncology. 1998 Mar-Apr;55(2):130-8. (PMID: 9499187)

EC 3.4.21.5 (Thrombin)

Date Created: 20180622 Date Completed: 20181127 Latest Revision: 20220409

20221213

PMC6013150

10.1371/journal.pone.0193657

29927924